(19)
(11) EP 1 998 799 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
05.03.2014 Bulletin 2014/10

(45) Mention of the grant of the patent:
25.12.2013 Bulletin 2013/52

(21) Application number: 07752573.1

(22) Date of filing: 06.03.2007
(51) International Patent Classification (IPC): 
C07K 16/00(2006.01)
C07K 1/00(2006.01)
C07K 16/46(2006.01)
A61P 35/00(2006.01)
C12P 21/08(2006.01)
C07K 16/28(2006.01)
A61K 39/395(2006.01)
(86) International application number:
PCT/US2007/005884
(87) International publication number:
WO 2007/103470 (13.09.2007 Gazette 2007/37)

(54)

HUMANIZED ANTI-CD22 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE

HUMANISIERTE ANTI-CD22-ANTIKÖRPER UND IHRE VERWENDUNG FÜR DIE BEHANDLUNG VON KREBS, TRANSPLANTATIONEN UND AUTOIMMUNERKRANKUNGEN

ANTICORPS HUMANISÉS DIRIGÉS CONTRE L'ANTIGÈNE CD22 ET LEUR UTILISATION À DES FINS THÉRAPEUTIQUES EN ONCOLOGIE, AINSI QUE DANS LE CADRE DE TRANSPLANTATIONS ET DE MALADIES AUTO-IMMUNES


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR MK RS

(30) Priority: 06.03.2006 US 779806 P

(43) Date of publication of application:
10.12.2008 Bulletin 2008/50

(60) Divisional application:
13159009.3 / 2639242

(73) Proprietor: MedImmune, LLC
Gaithersburg, MD 20878 (US)

(72) Inventors:
  • HILBERT, David
    Bethesda, MD 20817 (US)
  • JONES, Tarran
    Hertforshire WD7 8AG (GB)
  • WILLIAMS, David, G.
    Surrey KT18 7LY (GB)

(74) Representative: Gibbs, Richard 
Marks & Clerk LLP Aurora 120 Bothwell Street
Glasgow G2 7JS
Glasgow G2 7JS (GB)


(56) References cited: : 
WO-A1-94/27638
WO-A2-2007/103469
US-A1- 2004 001 828
US-A1- 2007 264 260
WO-A2-03/093320
US-A1- 2003 202 975
US-A1- 2005 118 182
   
  • TUSCANO JOSEPH M ET AL: "Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts." BLOOD 1 MAY 2003, vol. 101, no. 9, 1 May 2003 (2003-05-01), pages 3641-3647, XP002540281 ISSN: 0006-4971
  • O'DONNELL ROBERT T ET AL: "Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy." CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII OCT 2009, vol. 58, no. 10, October 2009 (2009-10), pages 1715-1722, XP002540282 ISSN: 1432-0851
  • ENGEL P ET AL: "THE SAME EPITOPE ON CD22 OF LYMPHOCYTES MEDIATES THE ADHESION OF ERYTHROCYTES, T AND B LYMPHOCYTES, NEUTROPHILS, AND MONOCYTES" JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 150, no. 11, 1 June 1993 (1993-06-01) , pages 4719-4732, XP000999233 ISSN: 0022-1767
  • TUSCANO ET AL.: 'Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficaci of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts' BLOOD vol. 101, no. 9, May 2003, pages 3641 - 3647, XP002540281
  • TUSCANO ET AL.: 'Engagement of the adhesion receptor CD22 triggers a potent stimulatory signal for B cells and blocking CD22/CD22L interactions impairs T-cell proliferation' BLOOD vol. 87, no. 11, 1996, pages 4723 - 4730, XP008130974
  • ENGEL ET AL.: 'The same epitope on CD22 of B lymphocytes medaites the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes' J. IMMUNOL. vol. 150, no. 11, 1993, pages 4719 - 4732, XP000999233
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).